Carfilzomib公司
医学
来那度胺
多发性骨髓瘤
内科学
累积发病率
移植
外科
自体干细胞移植
微小残留病
肿瘤科
随机对照试验
无进展生存期
临床研究阶段
随机化
总体生存率
造血干细胞移植
入射(几何)
泌尿科
梅尔法兰
维持疗法
胃肠病学
沙利度胺
进行性疾病
存活率
临床终点
性能状态
阶段(地层学)
置信区间
作者
Giuseppe Bertuglia,Mattia D’Agostino,Delia Rota‐Scalabrini,Angelo Belotti,L. Paris,Micol Quaresima,Sonia Morè,Stelvio Ballanti,Sara Aquino,Paolo de Fabritiis,Francesca Fioritoni,Michele Cea,Nicola Giuliani,Francesca F. Patriarca,Stefania Oliva,Massimo Gentile,Francesca Fazio,Renato Zambello,Sara Bringhen,Paolo Corradini
出处
期刊:Blood
[Elsevier BV]
日期:2026-11-16
标识
DOI:10.1182/blood.2026035635
摘要
In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643
科研通智能强力驱动
Strongly Powered by AbleSci AI